ATE538652T1 - Synergistische pharmazeutische kombination für die behandlung von krebs - Google Patents

Synergistische pharmazeutische kombination für die behandlung von krebs

Info

Publication number
ATE538652T1
ATE538652T1 AT07735911T AT07735911T ATE538652T1 AT E538652 T1 ATE538652 T1 AT E538652T1 AT 07735911 T AT07735911 T AT 07735911T AT 07735911 T AT07735911 T AT 07735911T AT E538652 T1 ATE538652 T1 AT E538652T1
Authority
AT
Austria
Prior art keywords
cancer
treatment
pharmaceutical combination
synergistic pharmaceutical
synergistic
Prior art date
Application number
AT07735911T
Other languages
English (en)
Inventor
Maggie Rathos
Kalpana Joshi
Harshal Khanwalkar
Somesh Sharma
Original Assignee
Piramal Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Life Sciences Ltd filed Critical Piramal Life Sciences Ltd
Application granted granted Critical
Publication of ATE538652T1 publication Critical patent/ATE538652T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT07735911T 2007-05-15 2007-05-15 Synergistische pharmazeutische kombination für die behandlung von krebs ATE538652T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2007/051841 WO2008139271A2 (en) 2007-05-15 2007-05-15 A synergistic pharmaceutical combination for the treatment of cancer

Publications (1)

Publication Number Publication Date
ATE538652T1 true ATE538652T1 (de) 2012-01-15

Family

ID=40002696

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07735911T ATE538652T1 (de) 2007-05-15 2007-05-15 Synergistische pharmazeutische kombination für die behandlung von krebs

Country Status (18)

Country Link
US (1) US8822526B2 (de)
EP (1) EP2154971B1 (de)
JP (1) JP5688288B2 (de)
KR (1) KR101403100B1 (de)
CN (1) CN101677567B (de)
AR (1) AR066564A1 (de)
AT (1) ATE538652T1 (de)
AU (1) AU2007353129B2 (de)
BR (1) BRPI0721626A2 (de)
CA (1) CA2687204C (de)
DK (1) DK2154971T3 (de)
ES (1) ES2380129T3 (de)
IL (1) IL202014A (de)
MX (1) MX2009012155A (de)
NZ (1) NZ581183A (de)
PT (1) PT2154971E (de)
TW (1) TWI449525B (de)
WO (1) WO2008139271A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI461194B (zh) 2009-05-05 2014-11-21 Piramal Entpr Ltd 吡咯啶取代黃酮作為輻射致敏劑
US20120009203A1 (en) * 2010-06-29 2012-01-12 Anahid Jewett Depletion of cancer stem cells
US9763982B2 (en) 2010-06-29 2017-09-19 The Regents Of The University Of California Depletion of cancer stem cells
WO2012069972A1 (en) 2010-11-19 2012-05-31 Piramal Life Sciences Limited A pharmaceutical combination for the treatment of breast cancer
CA2818229A1 (en) * 2010-11-19 2012-05-24 Piramal Enterprises Limited Pharmaceutical combination of paclitaxel and a cdk inhibitor
TW201242597A (en) 2011-03-14 2012-11-01 Piramal Life Sciences Ltd A synergistic pharmaceutical combination for the treatment of pancreatic cancer
TW201300105A (zh) * 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
CN103648588A (zh) 2011-06-24 2014-03-19 皮拉马尔企业有限公司 治疗人类乳头状瘤病毒相关癌症的化合物
EP3019166B1 (de) * 2013-07-12 2019-05-08 Piramal Enterprises Limited Pharmazeutische zusammensetzungen zur behandlung von melanomen
WO2016172214A1 (en) 2015-04-20 2016-10-27 Tolero Pharmaceuticals, Inc. Predicting response to alvocidib by mitochondrial profiling
DK3527574T3 (da) 2015-05-18 2022-06-27 Sumitomo Pharma Oncology Inc Alvocidib-prodrugs, der har øget biotilgængelighed
AU2016301315C1 (en) 2015-08-03 2022-07-07 Sumitomo Pharma Oncology, Inc. Combination therapies for treatment of cancer
KR102275758B1 (ko) * 2016-03-28 2021-07-12 프레시지 바이오싸이언시스, 인크. 암 치료를 위한 제약학적 조합물
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
US11994511B2 (en) 2017-04-04 2024-05-28 University Of Miami Biomarkers indicative of prostate cancer and treatment thereof
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
US11510943B2 (en) * 2018-03-12 2022-11-29 Yeditepe Universitesi Chemotherapeutic agent comprising combination of alexidine dihydrochloride and sodium pentaborate pentahydrate
WO2020117988A1 (en) 2018-12-04 2020-06-11 Tolero Pharmaceuticals, Inc. Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
RU2710273C1 (ru) * 2019-04-24 2019-12-25 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Фармацевтическая композиция для лечения злокачественных новообразований
CN114767669B (zh) * 2022-05-20 2023-07-04 湖南省中医药研究院 一种P-gp抑制剂及其提取方法和应用
CN116083566B (zh) * 2022-09-06 2025-10-17 复旦大学附属金山医院(上海市金山区眼病防治所、上海市金山区核化伤害应急救治中心) Cdk14的抑制剂在卵巢癌紫杉醇化疗耐药中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7915301B2 (en) * 2002-07-08 2011-03-29 Piramal Life Science Limited Inhibitors of cyclin dependent kinases and their use
TWI331034B (en) * 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
US7271193B2 (en) * 2002-07-08 2007-09-18 Nicholas Piramal India, Ltd. Inhibitors of cyclin-dependent kinases and their use
US7884127B2 (en) * 2002-07-08 2011-02-08 Pirimal Life Sciences Ltd. Inhibitors of cyclin dependent kinases and their use
EP1558289A1 (de) * 2002-11-06 2005-08-03 Cyclacel Limited Pharmazeutische zusammensetzung mit einem cdk-hemmer und gemcitabin
CA2548491A1 (en) * 2003-12-08 2005-06-23 The Arizona Board Of Regents On Behalf Of The University Of Arizona Synergistic anti-cancer compositions
JP2008533039A (ja) * 2005-03-11 2008-08-21 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 抗アポトーシスＢｃｌ−２ファミリーメンバーのクロメン−４−オン阻害剤およびその使用

Also Published As

Publication number Publication date
EP2154971A2 (de) 2010-02-24
WO2008139271A2 (en) 2008-11-20
EP2154971B1 (de) 2011-12-28
US20100305057A1 (en) 2010-12-02
CN101677567B (zh) 2013-06-19
DK2154971T3 (da) 2012-04-02
CN101677567A (zh) 2010-03-24
EP2154971A4 (de) 2010-05-19
BRPI0721626A2 (pt) 2013-01-22
IL202014A0 (en) 2010-06-16
AU2007353129A1 (en) 2008-11-20
JP2010526862A (ja) 2010-08-05
AR066564A1 (es) 2009-08-26
US8822526B2 (en) 2014-09-02
NZ581183A (en) 2012-03-30
PT2154971E (pt) 2012-04-10
MX2009012155A (es) 2010-01-15
KR20100017763A (ko) 2010-02-16
CA2687204A1 (en) 2008-11-20
JP5688288B2 (ja) 2015-03-25
ES2380129T3 (es) 2012-05-08
IL202014A (en) 2014-06-30
AU2007353129B2 (en) 2014-02-20
TW200913991A (en) 2009-04-01
CA2687204C (en) 2015-11-24
TWI449525B (zh) 2014-08-21
KR101403100B1 (ko) 2014-06-19
WO2008139271A3 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
ATE538652T1 (de) Synergistische pharmazeutische kombination für die behandlung von krebs
IL255752B (en) Compounds, pharmaceutical compositions comprising the same and uses thereof for treating cardiovasclar disease, an inflammatory disease or cancer
HUE054495T2 (hu) Rák kezelésére szolgáló készítmény
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
DK2121139T3 (da) Formulations for cancer treatment
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
BRPI0917444A2 (pt) composições farmacêuticas de retenção gástrica para o tratamento e prevenção de doenas do snc
PL2152237T3 (pl) Nowa kompozycja farmaceutyczna
EP2415763A4 (de) Pharmazeutische zusammensetzungen zur behandlung oder prävention von glaukom
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
DK2056842T3 (da) Modificeret galactosylceramid til behandling af cancerøse sygdomme
HRP20181843T1 (hr) Sredstvo za izdavanje lijeka za životinje
BRPI0911577A2 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
BRPI0911112A2 (pt) composições e métodos para o tratamento do câncer de mama
BR112012002265A2 (pt) composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios
BRPI0813670A2 (pt) Compostos para tratamento
SMT201500189T1 (it) Ligandi sigma per la prevenzione o il trattamento del dolore indotto da chmioterapia
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BRPI0908635A2 (pt) composto, composição farmacêutica e método de tratamento de câncer
IT1391866B1 (it) Composizione iniettabile di polinucleotidi per il trattamento di patologie osteoarticolari.
BRPI0922884A2 (pt) compostos para tratamento de câncer
BRPI0811919A2 (pt) Medicamento para tratamento do mal de alzheimer
BRPI1009448A2 (pt) combinações farmacêuticas compreendendo edea119/bay 869766 para o tratamento de cânceres específicos
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.